Literature DB >> 17607586

Umbilical cord blood transplantation using non-myeloablative conditioning: the Mexican experience.

Consuelo Mancías-Guerra1, Guillermo J Ruiz-Delgado, Carlos Manzano, Maria Angeles Díaz-Hernandez, Luz C Tarín-Arzaga, Oscar González-Llano, David Gómez-Almaguer, Guillermo J Ruiz-Argüelles.   

Abstract

Twenty-eight children and adults underwent transplantation with allogeneic umbilical cord blood cells (UCB) using a non-ablative conditioning regimen; there were 15 males and 13 females. Seven patients were grafted because a non-malignant condition and 21 for a malignant disease. The median age was 8 years (range 4 months-72 years). Ten UCB were obtained from Mexican cord bloods banks, five cords were from compatible siblings and the remaining 13 cords were obtained from abroad. Median time to recover >0.5 x 10(9)/l granulocytes was 24 days (range 8-32 days), whereas median time to recover >20 x 10(9)/l platelets was 26 days (range 12-50 days). Twelve recipients never engrafted and recovered subsequently endogenous hematopoiesis. The non-engraftment rate was significantly higher in patients allografted for benign conditions (71%) than in those allografted for malignant conditions (28%). The median overall post-transplant survival (SV) was 33 months and the 73-months overall SV was 39%. The cumulative incidence of grade II-IV acute GVHD and grade III-IV GVHD for the entire cohort of patients were 14 and 7%, respectively. Additional studies are needed to define if non-myeloablative conditioning is preferable over conventional conditioning in the case of UCB allografting.

Entities:  

Mesh:

Year:  2006        PMID: 17607586     DOI: 10.1080/10245330600921980

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  3 in total

Review 1.  Haploidentical Bone Marrow Transplantation in 2015 and Beyond.

Authors:  Guillermo J Ruiz-Argüelles; Guillermo J Ruiz-Delgado; Oscar González-Llano; David Gómez-Almaguer
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

2.  Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Authors:  F Ostronoff; F Milano; T Gooley; J A Gutman; P McSweeney; F B Petersen; B M Sandmaier; R Storb; C Delaney
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

3.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.